Chinook Therapeutics CVR
13F holders, Q1 2025 (March 31)5holders −1
1new positions
2sold out
$0.33avg. 13F price*
At the end of Q1 2025, 5 institutions reported holding Chinook Therapeutics CVR in their 13F filings, down 1 from Q4 2024. 1 opened new positions and 2 sold out. The largest holders were Erste Asset Management GmbH ($120K), Propel Bio Management, LLC ($39K) and Rhumbline Advisers ($0).
- Company
- Chinook Therapeutics CVR
- CUSIP
- 169CVR016
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 2 | $6 |
All 13F filers, Q4 2024 → Q1 2025: 30 shares bought and 63,042 shares sold, net −63,012 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Erste Asset Management GmbH | 0.00% | No change | 307,769 | $120K |
| Propel Bio Management, LLC | 0.04% | No change | 79,357 | $39K |
| Rhumbline Advisers | 0.00% | Reduce -3.3% | 87,734 | $0 |
| Sterling Capital Management LLC | 0.00% | No change | 1,053 | $0 |
| ORG Partners LLC | 0.00% | New | 30 | $0 |
"% of holder's portfolio" is CHINOOK THERAPEUTICS CVR's weight in each manager's 13F, not the share of Chinook Therapeutics CVR the manager owns.